Skip to main content
. 2021 Jul 13;62(9):2142–2150. doi: 10.1111/epi.17007

FIGURE 4.

FIGURE 4

Long‐term retention rates during open‐label extension (OLE) studies. BRV, brivaracetam; CNB, cenobamate; LAC, lacosamide; LEV, levetiracetam; PER, perampanel